Skip to main content
SpringerLink
Log in

CKD: understanding the high burden of disease, healthcare costs and mortality in the US

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Dapagliflozin and Prevention of Adverse Outcomes in CKD

  2. The study was supported by AstraZeneca.

Reference

  • Olufade T, et al. Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants. Advances in Therapy : 20 Jan 2021. Available from: URL: http://doi.org/10.1007/s12325-020-01609-2

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

CKD: understanding the high burden of disease, healthcare costs and mortality in the US. PharmacoEcon Outcomes News 871, 8 (2021). https://doi.org/10.1007/s40274-021-7446-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7446-0

Search

Navigation